Non-Covalent BTK Inhibitor Yields High Response Rate in Pretreated CLL
The non-covalent or reversible Bruton tyrosine kinase (BTK) inhibitor…
Browsing Tag
BTK
Nurix Therapeutics Presents Data at the American Association for Cancer Research…
<!-- Name:DistributionId Value:8808477 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Michael Wang on the Reversible BTK Inhibitor for Previously Treated MCL
The FDA recently granted accelerated approval to pirtobrutinib (Jaypirca), a reversible Bruton's tyrosine…
Reversible BTK Inhibitor Gets FDA Nod for Mantle Cell Lymphoma
The FDA has granted accelerated approval to pirtobrutinib (Jaypirca), a non-covalent or…
FDA Greenlights BTK Inhibitor Zanubrutinib for CLL/SLL
The FDA has approved the Bruton's tyrosine kinase (BTK) inhibitor zanubrutinib (Brukinsa)…
Nurix Therapeutics Presents Positive Clinical Results from its Novel BTK Degrader…
Treatment with NX-2127 provides clinically meaningful responses in heavily pretreated chronic lymphocytic leukemia (CLL) patients regardless of Bruton’s tyrosine kinase (BTK) mutational…
Novel BTK Inhibitor Looks Good for Sjogren’s Syndrome
PHILADELPHIA -- Remibrutinib, an investigational Bruton's tyrosine kinase (BTK) inhibitor, appeared effective in reducing signs…
Third-Line BTK Inhibitor Combo Doubles PFS in Follicular Lymphoma
CHICAGO -- A third-line combination involving a newer-generation Bruton's tyrosine kinase (BTK) inhibitor plus obinutuzumab (Gazyva)…
Ibrutinib with chemoimmunotherapy improved progression-free survival for newly…
Combination chemoimmunotherapy with the Bruton's tyrosine kinase (BTK) inhibitor ibrutinib demonstrated improved progression-free survival over standard chemoimmunotherapy for previously…
BTK Inhibitor Shows Potential in Immune Thrombocytopenia
An investigational oral Bruton's tyrosine kinase (BTK) inhibitor was tolerable and yielded rapid…